Genmab A/S reports Q1 2026 worldwide net sales of DARZALEX at USD 3.96 billion, driven by strong U.S. demand and continued uptake of the subcutaneous DARZALEX FASPRO formulation under its royalty agreement with Johnson & Johnson.
Written By: Vennela Reddy, BPharm
Reviewed By: Pharmacally Editorial Team
Genmab A/S reported that worldwide net trade sales of DARZALEX (daratumumab) reached USD 3,964 million in the first quarter of 2026, based on sales reported by Johnson & Johnson through its legal entity Janssen Biotech, Inc. The total includes both intravenous daratumumab and the subcutaneous formulation.
U.S. net trade sales accounted for USD 2,208 million, while USD 1,756 million came from markets outside the United States. The reported figures also include the subcutaneous combination daratumumab and hyaluronidase-fihj, marketed in the U.S. as DARZALEX FASPRO.
Under the companies’ exclusive worldwide licensing agreement, Genmab receives royalties on global net sales of DARZALEX across both intravenous and subcutaneous formulations. Johnson & Johnson holds rights to develop, manufacture, and commercialize daratumumab globally, while Genmab participates economically through royalty payments tied to product performance.
DARZALEX (daratumumab) is a CD38-directed monoclonal antibody approved for the treatment of patients with multiple myeloma, where it works by binding to CD38 expressed on myeloma cells and triggering immune-mediated tumor cell death. The therapy is available as an intravenous infusion and as DARZALEX FASPRO, a subcutaneous formulation that combines daratumumab with hyaluronidase to enable faster administration under the skin.
DARZALEX FASPRO provides similar efficacy to the IV formulation while reducing infusion time and improving convenience, supporting its use across multiple lines of therapy either as monotherapy or in combination with standard anti-myeloma regimens.
The Q1 2026 performance reinforces DARZALEX as a major revenue driver in multiple myeloma, with continued contribution from both established intravenous use and the expanding uptake of the subcutaneous formulation.
Reference
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2026 – Genmab A/S
About the Writer
Vennela Reddy, B.Pharm is a pharmacy graduate with a keen interest in clinical research, pharmacovigilance, and medical writing, with a growing focus on publishable and scientific content development. In her words, she is passionate about translating complex medical data into clear, evidence-based communication.